definiens: shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy ( ALD)(including but not limited to AMN, CCALD, and all other variants of this disease caused by geneticmutations ), beta hemoglobinopathies ( including but not limited to beta - thalassemia and sickle cell anemia ), [ * * * ], the includes in vivo as well as ex vivo gene therapy . Licensee and/or Affiliates shall have theright to request Institut Pasteur to expand the definition of to include additional clinical areas . [ * * * ] For clarity, the Field excludes any other fields and specifically prophylactic and therapeutic human andveterinary vaccination against all kind of pathogens, and the field of services of production andcommercialisation of Good Manufacturing Practice ( GMP ) batches of lentiviral vectors for clinical trials . Forclarity, the Field shall include production of GMP batches, by Licensee and its Affiliates [ * * * ] . For clarity, Institut Pasteur has already granted exclusive rights for services of production and commercialisation of GoodManufacturing Practice ( GMP ) batches of lentiviral vectors for clinical trials . [ * * * ] • shall mean any new invention, patentable or not, patented or not, of the Technology, whichunder applicable law, depends on, at least, one claim of the Patents . For clarity, an Improvement does notinclude any Product . CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH . ACOMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THESECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIALTREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED